Abstract
To overcome gene therapy barriers such as low transfection efficiency and non-specific delivery, liposomal nanoparticles targeted by a single chain antibody fragment to the transferrin receptor (TfRscFv) delivering wild type human p53 (SGT-53) were developed for tumor-specific targeting. We hypothesize that SGT-53 in combination with gemcitabine will demonstrate enhanced therapeutic benefit in an in vivo metastatic pancreatic cancer model.
Full Text 
Sign-in/Register to access full text options
Sign-in/Register to access full text options 
Published version (
Free)
Free) 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call
